These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 31322176)
1. Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27. Li J; Zhang X; Shen J; Guo J; Wang X; Liu J Mol Med Rep; 2019 Sep; 20(3):2410-2418. PubMed ID: 31322176 [TBL] [Abstract][Full Text] [Related]
2. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells. Kacı FN; Kiraz Y; Çekdemir D; Baran Y Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493 [TBL] [Abstract][Full Text] [Related]
3. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. Que W; Chen J; Chuang M; Jiang D APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676 [TBL] [Abstract][Full Text] [Related]
4. [Study of the effects Tian Y; Li LH; Yang GZ; Chen WM Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):976-981. PubMed ID: 27995884 [TBL] [Abstract][Full Text] [Related]
5. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690 [TBL] [Abstract][Full Text] [Related]
6. Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27. Kong XX; Jiang S; Liu T; Liu GF; Dong M Biomed Pharmacother; 2020 Dec; 132():110907. PubMed ID: 33113434 [TBL] [Abstract][Full Text] [Related]
7. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells. Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872 [TBL] [Abstract][Full Text] [Related]
8. [Atractylenolide I Can Induce Apoptosis of U266 Cells and Enhance Bortezomib Effect]. Mai ZX; Yu TQ; Fan TT Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):177-184. PubMed ID: 32027273 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327 [TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo. Jia C; Kong D; Guo Y; Li L; Quan L Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410 [TBL] [Abstract][Full Text] [Related]
13. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis. Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237 [TBL] [Abstract][Full Text] [Related]
14. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway. Wang Y; Zhang XL; Sun CM Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2564-2571. PubMed ID: 29771406 [TBL] [Abstract][Full Text] [Related]
15. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis. Oudaert I; Satilmis H; Vlummens P; De Brouwer W; Maes A; Hose D; De Bruyne E; Ghesquière B; Vanderkerken K; De Veirman K; Menu E J Exp Clin Cancer Res; 2022 Feb; 41(1):45. PubMed ID: 35105345 [TBL] [Abstract][Full Text] [Related]
16. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma. Li X; Yang Y; Yi X Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769 [TBL] [Abstract][Full Text] [Related]
17. [Mechanism and Clinical Significance of Wang YR; Ma YP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):138-145. PubMed ID: 38387912 [TBL] [Abstract][Full Text] [Related]
18. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312 [TBL] [Abstract][Full Text] [Related]
19. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling. Xu B; Li J; Xu D; Ran Q Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865 [TBL] [Abstract][Full Text] [Related]
20. Increased fatty acid synthase as a potential therapeutic target in multiple myeloma. Wang WQ; Zhao XY; Wang HY; Liang Y J Zhejiang Univ Sci B; 2008 Jun; 9(6):441-7. PubMed ID: 18543396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]